Beyond EtO: A New Chapter for US Sterilization

Regulatory scrutiny and fresh capital spur interest in new methods, even as ethylene oxide remains central to device supply chains

12 Sep 2025

The US sterilization market is showing early signs of change as tighter environmental oversight and new capital push manufacturers to consider alternatives to ethylene oxide, long the dominant method for complex medical devices.

Ethylene oxide, or EtO, remains widely used because it can sterilize heat-sensitive and intricate products at scale. However, increased scrutiny from regulators over emissions and worker safety has led to stricter controls, longer permitting timelines and, in some cases, operational disruptions at contract sterilization facilities. Manufacturers say these pressures have slowed product launches and added strain to supply chains.

In response, companies are examining whether additional sterilization methods can reduce exposure to regulatory and capacity risks. A recent example is growth funding from NewVale Capital for Noxilizer, aimed at expanding the commercial rollout of nitrogen dioxide sterilization. The investment signals confidence that certain alternatives may be viable beyond niche applications.

Nitrogen dioxide is attracting attention for its relatively straightforward operating model. It can sterilize some sensitive devices, offers shorter cycle times than certain traditional approaches and can be installed closer to manufacturing sites. For producers reliant on centralised EtO facilities, this flexibility may provide a buffer against bottlenecks.

Contract sterilization providers have also reported greater customer interest in using more than one sterilization modality. Companies including Sterigenics have noted that clients are exploring diversified strategies to manage the risk of regulatory delays or temporary site closures. Investment activity and selective consolidation across the sector suggest operators are preparing for a more demanding compliance environment.

Despite the momentum, alternatives face practical limits. Validation and regulatory approval processes can be lengthy, particularly for devices already cleared using EtO. Many products still require the material compatibility and penetration properties that EtO provides.

For now, the shift appears incremental rather than transformative. Broader access to alternative technologies may ease capacity constraints and improve resilience, but ethylene oxide continues to underpin much of the US medical device sterilization system.